Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Fig. 1

Swim lane plot for duration of response based on central review in daratumumab-treated responders. Responses are shown (PR). Five patients had progressive disease (PD) and 2 patients discontinued treatment based on investigator’s assessment of PD (*) and no further assessment of response occurred due to withdrawal from study. The arrow indicates ongoing treatment at clinical cutoff date (1 patient). PD, progressive disease; PR, partial response

Back to article page
\